Abstract
In normal healthy tissues, an equilibrium is established between cell death and survival. This equilibrium ensures that cells survive in the right milieu, but undergo programmed cell death (apoptosis) when damaged, or when the environment is no longer supportive. Diseases may occur with alterations in this homeostasis. For example, cancer cells may survive in an environment in which they would not normally exist. This is accomplished by alterations in the expressions or functions of genes controlling both survival and apoptotic signaling pathways. Survival signaling pathways involve the activation of cell surface receptors, serine threonine kinases, transcription factors as well as other molecules. In breast and ovarian cancers, the ErbB2 growth factor receptor is overexpressed and this contributes to the progression of these cancers, in part by constitutively activating survival signaling pathways. In contrast, apoptotic signal transduction pathways are often inhibited in cancer. For example, overexpression of Bcl-2 blocks apoptosis and this contributes to the accumulation of cells in follicular lymphomas and chronic lymphocytic leukemia. Furthermore, alterations in these signaling pathways in cancer cells may lead to drug resistance. Recent advances in molecular targeted therapies have taken advantage of alterations in survival and apoptotic signaling pathways in cancer to specifically target aberrantly regulated molecules. For example, Herceptin inhibits ErbB2 function and antisense oligonucleotides against Bcl-2 reduce Bcl-2 expression. These agents can thus induce apoptosis in the specific cancer cell against which they have been targeted. In this review, we will discuss alteration in survival and apoptotic signal transduction pathways in cancer and the development of novel chemotherapeutic drugs to target these pathways.
Current Cancer Drug Targets
Title: Changes in the Apoptotic and Survival Signaling in Cancer Cells and Their Potential Therapeutic Implications
Volume: 4 Issue: 2
Author(s): Albert F. Kabore, James B. Johnston and Spencer B. Gibson
Affiliation:
Keywords: lymphomas, Herceptin, apoptosis
Abstract: In normal healthy tissues, an equilibrium is established between cell death and survival. This equilibrium ensures that cells survive in the right milieu, but undergo programmed cell death (apoptosis) when damaged, or when the environment is no longer supportive. Diseases may occur with alterations in this homeostasis. For example, cancer cells may survive in an environment in which they would not normally exist. This is accomplished by alterations in the expressions or functions of genes controlling both survival and apoptotic signaling pathways. Survival signaling pathways involve the activation of cell surface receptors, serine threonine kinases, transcription factors as well as other molecules. In breast and ovarian cancers, the ErbB2 growth factor receptor is overexpressed and this contributes to the progression of these cancers, in part by constitutively activating survival signaling pathways. In contrast, apoptotic signal transduction pathways are often inhibited in cancer. For example, overexpression of Bcl-2 blocks apoptosis and this contributes to the accumulation of cells in follicular lymphomas and chronic lymphocytic leukemia. Furthermore, alterations in these signaling pathways in cancer cells may lead to drug resistance. Recent advances in molecular targeted therapies have taken advantage of alterations in survival and apoptotic signaling pathways in cancer to specifically target aberrantly regulated molecules. For example, Herceptin inhibits ErbB2 function and antisense oligonucleotides against Bcl-2 reduce Bcl-2 expression. These agents can thus induce apoptosis in the specific cancer cell against which they have been targeted. In this review, we will discuss alteration in survival and apoptotic signal transduction pathways in cancer and the development of novel chemotherapeutic drugs to target these pathways.
Export Options
About this article
Cite this article as:
Kabore F. Albert, Johnston B. James and Gibson B. Spencer, Changes in the Apoptotic and Survival Signaling in Cancer Cells and Their Potential Therapeutic Implications, Current Cancer Drug Targets 2004; 4 (2) . https://dx.doi.org/10.2174/1568009043481551
DOI https://dx.doi.org/10.2174/1568009043481551 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Selectivity, Binding Affinity, and Ionization State of Matrix Metalloproteinase Inhibitors
Current Pharmaceutical Design Cardioprotection by Targeting the Pool of Resident and Extracardiac Progenitors
Current Drug Targets Natural Products Targeting Autophagy via the PI3K/Akt/mTOR Pathway as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Epigenetic Multiple Modulators
Current Topics in Medicinal Chemistry Role of Infrared Spectroscopy and Imaging in Cancer Diagnosis
Current Medicinal Chemistry Anti-Metastatics: An Overview of Drug Candidates in Current Pipelines
Current Pharmaceutical Design Antibody-Targeted Immunoliposomes for Cancer Treatment
Mini-Reviews in Medicinal Chemistry Inhibition of V-ATPase and Carbonic Anhydrases as Interference Strategy with Tumor Acidification Processes
Current Pharmaceutical Design General Principles for the Treatment of Non-Infectious Uveitis
Inflammation & Allergy - Drug Targets (Discontinued) Nanotechnology for Nanomedicine and Delivery of Drugs
Current Pharmaceutical Design A Combined Approach with Rituximab Plus Anti-TRAIL-R Agonistic Antibodies for the Treatment of Haematological Malignancies
Current Pharmaceutical Design Prognostic Markers in Small Cell Lung Cancer
Current Cancer Therapy Reviews Development of Anti-Atherosclerosis Therapy Based on the Inflammatory and Proliferative Aspects of the Disease
Current Pharmaceutical Design Therapeutic Targets in Triple Negative Breast Cancer - Where are we now?
Recent Patents on Anti-Cancer Drug Discovery Role of MicroRNA 21 in Mesenchymal Stem Cell (MSC) Differentiation: A Powerful Biomarker in MSCs Derived Cells
Current Pharmaceutical Biotechnology Application of dsRNA in Cancer Immunotherapy: Current Status and Future Trends
Anti-Cancer Agents in Medicinal Chemistry Proteasome Inhibition as a New Therapeutic Principle in Hematological Malignancies
Current Drug Targets PI3K/AKT/mTOR Inhibitors In Ovarian Cancer
Current Medicinal Chemistry An Overview of the α4β1 Integrin and the Potential Therapeutic Role of its Antagonists
Current Medicinal Chemistry Targeting the Process of Farynesylation for Therapy of Hematologic Malignancies
Current Molecular Medicine